Phase 2 multicenter dose-ranging trial of TLK286 (Canfosfamide HCl) (T) in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)
Sequist L, Fidas P, Temel J, Kolevska T, Rabin M, Boccia R, Burris H, Belt R, Kosmo M, Huberman M, Melnyk O, Guba S, Sleckman B, Klix M, Needles B, Mills G, Englund C, Caldwell D, Tesarowski D, Brown G, Edelman M, Lynch T. Phase 2 multicenter dose-ranging trial of TLK286 (Canfosfamide HCl) (T) in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Proceedings of the 2007 Annual Meeting of the American Association for Cancer Research. 2007; abstract 3521.